Search

314 results for "lecanemab".

Research summaries 285

Showing the best 200 of 285, 181–190, page 19 of 20. Filter these by subject, year and score in the research library →

1. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/the-ahead-3-45-study-design-of-a-prevention-trial-for-alzheimer-s-35971310

   … will test whether with lecanemab (BAN2401) can slow the accumulation of tau and prevent the cognitive decline associated with AD during its preclinical stage. Eligibility to randomize into the A3 Trial or A45 Trial is based on …

2. β-Amyloid PET Signal Reduction in Prior ARIA-E Regions after Antiamyloid Therapy for Alzheimer DiseaseResearch summary

   Research summaries · alzhub.org/study/amyloid-pet-signal-reduction-in-prior-aria-e-regions-after-41260674

   In 4 of 5 patients treated with lecanemab or donanemab and who had moderate or severe ARIA-E, Aβ PET signal decreased significantly more in regions that had been involved with ARIA-E. Greater regional Aβ PET signal reduction in …

3. A Review of Clinical Biomarker Insights: Advances in Diagnosis and Prognosis of Early AlzheimerResearch summary

   Research summaries · alzhub.org/study/a-review-of-clinical-biomarker-insights-advances-in-diagnosis-and-5adb338a

   … such as donanemab and lecanemab, may be able to delay the progression of AD. This review reports that plasma NEFL, GFAP and GDF15 were consistently linked with incident dementia and Alzheimer's, and that an individual with …

4. Alzheimer's Disease: Treatment Challenges for the FutureResearch summary

   Research summaries · alzhub.org/study/alzheimer-s-disease-treatment-challenges-for-the-future-40739944

   … disease. These antibodies, lecanemab and donanemab, mark a turning point for our understanding of the disease pathogenesis and for the treatment of this prevalent disorder. This review discusses what they imply for disease …

5. Amyloid-related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid-modifying therapyResearch summary

   Research summaries · alzhub.org/study/amyloid-related-imaging-abnormalities-aria-diagnosis-management-and-38939962

   … of aducanumab and now lecanemab warrant broader understanding by the health care provider continuum. The optimal care approach for patients with Alzheimer's dementia, treated with amyloid-targeted therapy, includes proper …

6. An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?Research summary

   Research summaries · alzhub.org/study/an-anti-amyloid-therapy-works-for-alzheimer-s-disease-why-has-it-36797987

   … the clinical trial of lecanemab in early Alzheimer’s disease, and the implications for the amyloid hypothesis. They argue that the results mark a turning point for the Alzheimer’s field, but that taking anti-amyloid therapies …

7. Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient SelectionResearch summary

   Research summaries · alzhub.org/study/anti-amyloid-monoclonal-antibodies-for-alzheimer-s-disease-evidence-41003140

   … regulatory outcomes. Lecanemab and donanemab showed more consistent cognitive benefits, while aducanumab yielded mixed findings, leading to its withdrawal. ARIAs were the most frequent adverse events, occurring more often in APOE …

8. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's DiseaseResearch summary

   Research summaries · alzhub.org/study/anti-amyloid-monoclonal-antibodies-for-the-treatment-of-alzheimer-s-37955845

   Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early Alzheimer's disease patients who have proven β-amyloid pathology (Aβ). One of …

9. Anticorpos anti-amiloide no tratamento da Doença de Alzheimer: uma revisão narrativaResearch summary

   Research summaries · alzhub.org/study/anticorpos-anti-amiloide-no-tratamento-da-doenca-de-alzheimer-uma-b2f98913

   … monoclonais, como Aducanumab, Lecanemab e Donanemab. Uma busca através do PubMed, utilizando os operadores booleanos "((anti-amyloid antibody)) and ((Alzheimer))", inicialmente identificou 418 artigos. Após a aplicação de …

10. Assessing the clinical meaningfulness of slowing CDR‐SB progression with disease‐modifying therapies for Alzheimer's diseaseResearch summary

    Research summaries · alzhub.org/study/assessing-the-clinical-meaningfulness-of-slowing-cdrsb-progression-39949872

    … = 2, treatment with lecanemab would extend independence in IADLs for 10 months (95% confidence interval [CI] 4-18 months) and treatment with donanemab in the low/medium tau group would extend independence in IADLs by 13 months …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

28781 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-06. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.